Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,624

Document Document Title
WO/2024/040768A1
Disclosed in the present invention are a 5-pyridine-1H-indazole compound, a pharmaceutical composition, and a use. The structure of the compound is represented by formula I or II, and also comprised are an isomer or pharmaceutically acce...  
WO/2024/032718A1
The present invention relates to a crystal form of a hepatitis C inhibitor and the use thereof in a drug, and specifically relates to a crystal form A of a compound as represented by formula (I), a pharmaceutical composition of the cryst...  
WO/2024/034644A1
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...  
WO/2024/028729A1
The present disclosure relates to processes for the fluorination of molecules. One aspect provides a process for incorporating a fluorine atom into a molecule, said process comprising converting a compound of formula X—SG into a compou...  
WO/2024/029877A1
The present invention provides novel purine derivative compounds as A3 adenosine receptor agonists, hydrates thereof, solvates thereof, or pharmaceutically acceptable salts thereof. The novel purine derivatives of the present invention h...  
WO/2024/024766A1
The purpose of the present invention is to provide an alkylating agent that can alkylate a hydroxyl group at 2' position of a synthetic intermediate for an amidite compound in the presence of a base. The present invention provides an alk...  
WO/2024/017375A1
A cyclic substituted compound for RNA capping and use thereof, belonging to the technical field of genetic engineering. The compound has a structure represented by formula (VI). The compound is used for capping an mRNA 5' end, such that ...  
WO/2024/016639A1
Provided are a preparation of an anti-viral-infection compound, a method, a compound of formula (I), and a method and intermediate for synthesizing the compound of formula (I). The compound can inhibit the replication of SARS-CoV-2 and c...  
WO/2024/019137A1
The present invention relates to a production method of an oligonucleotide that includes a step for condensing, in the presence of an activator, a compound represented by formula (2) [wherein: G2 represents a protecting group of the hydr...  
WO/2024/014770A1
The present application relates to a modified RNA for preparing a mRNA vaccine and therapeutic agent, the modified RNA, according to one aspect, comprising a specific chemical modification and genetic modification and thus being capable ...  
WO/2024/012126A1
Disclosed in the present invention is a cordycepin-derivatized compound with an anti-tumor effect, which has a structure as represented by formula I. The cordycepin derivative and a pharmaceutical composition thereof provided in the pres...  
WO/2024/013349A1
The inventors have now succeeded in developing compounds of Formula (I), described below, having the advantage of inhibiting NAD kinases, in particular P. aeruginosa NADK (PaNADK) enzyme, Listeria monocytogenes (LmNADK) enzyme and/or hum...  
WO/2024/007068A1
A process for extracting TTX from biological material containing TTX, wherein the process comprises steps of extracting with a first solvent, concentrating, washing with a second solvent, concentrating again and purifying by chromatography.  
WO/2024/010810A2
The disclosure provides conjugates including an Fc domain monomer or Fc domain covalently linked to a moiety that binds to or inhibits CD73. The disclosure also provides pharmaceutical compositions including such conjugates and uses of s...  
WO/2024/002112A1
The present invention relates to use of a compound represented by formula (I) in resisting feline coronavirus or calicivirus infection. The compound represented by formula (I) efficiently inhibits the replication of feline coronavirus or...  
WO/2024/002045A1
Provided is an oligonucleotide delivery agent comprising at least one lipid moiety comprising at least one linear alkyl group or linear alkylenyl group directly or indirectly conjugated to a single-stranded oligonucleotide, which can be ...  
WO/2024/006376A1
The disclosure provides solid forms, e.g. salts and polymorphs, of the compound of Formula (I) and uses thereof. Also provided are the methods of making the solid forms and pharmaceutical formulations comprising the solid forms.  
WO/2024/006461A1
The present disclosure relates to solid forms (e.g. crystalline forms, solvates, and crystalline forms thereof) of a compound which is ((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)- 5-cyano-3,4-dihydroxytetrahydrofuran-2-yl...  
WO/2024/002007A1
The present invention provides a double-stranded RNA comprising a nucleotide analog. The double-stranded RNA of the present invention exhibits one or more of enhanced stability, reduced off-target toxicity, and enhanced effectiveness.  
WO/2024/006953A2
The present disclosure relates to monomers and methods for synthesisizing modified oligonucleotides.  
WO/2023/249888A1
A composition that includes a micro-RNA mimic containing one or more cytosine nucleosides in which at least one cytosine nucleoside is replaced by cytosine arabinoside. Also provided is a method for killing a cancer cell by contacting it...  
WO/2023/250015A1
The present disclosure provides pyrimidine nucleoside compounds, including torcitabine, thymidine, deoxyuridine, deoxycytidine and uridine, and methods to treat telomere biology disorders (TBDs) and aging-related diseases, including hema...  
WO/2023/246860A1
The present invention provides an initially capped oligonucleotide primer, a method for preparing same, and use thereof, and particularly, provides an initially capped oligonucleotide primer comprising a hexose ring, a morpholine ring or...  
WO/2023/245040A1
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer and reverse fleximer nucleoside analogues having increased flexibility and ability to alter their conformat...  
WO/2023/241699A1
The present disclosure relates to a cyclopentyl adenosine derivative and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, whe...  
WO/2023/245037A1
The disclosure provides processes for preparing the compound of formula (VIa-1) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIa-1) are also provided.  
WO/2023/241587A1
The present invention provides an oligonucleotide having a cyclic phosphonate modification. The oligonucleotide of the present invention exhibits one or more among enhanced stability, reduced off-target toxicity, and enhanced effectiveness.  
WO/2023/239190A1
The present invention relates to a method for preparing 4'-thio-5-aza-2'-deoxycytidine which exhibits DNMT1 inhibitory activity. The production method according to the present invention can enhance reaction efficiency through efficient p...  
WO/2023/235362A1
Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped mRNA molecules, wherein the 5' end ...  
WO/2023/233410A1
The present invention relates to crystalline polymorph Form I of benzyl N2- ((benzyloxy)carbonyl)-N4-(l-((2R,3S,4S,5R)-3,4-dihydroxy-5-( hydroxymethyl)tetrahydrofuran- 2-yl)-2-oxo-l,2-dihydropyrimidin-4-yl)-L-asparaginate (Compound 1), p...  
WO/2023/229884A2
3'-blocked nucleotides, methods of deblocking the same, and methods of synthesizing polynucleotides using the same are provided herein. In some examples, a nucleotide is disposed within the aperture on the first side of a nanopore. The n...  
WO/2023/228177A1
The present invention relates to novel compositions comprising (l-((2R,3S,4S,5R)-3,4- dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-l,2-d ihydropyrimidin-4-yl)-L-asparagine (also known as BST-236, Astarabine® or Aspacytarabine)...  
WO/2023/230061A2
Disclosed herein are compounds of formula or pharmaceutically acceptable salts thereof, and methods of using the same for treating a viral infection or inhibiting replication of a virus.  
WO/2023/224108A1
Provided is a nucleoside represented by formula (1). [In formula (1): R1 represents a hydroxyl group, a hydroxyl group in which the hydrogen atom is substituted by an alkyl or alkenyl group, or a protected hydroxyl group; R2 represents a...  
WO/2023/225042A1
Compounds, methods, and compositions for treating or preventing viral infections using flexible nucleosides analogs. The fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to pro...  
WO/2023/219427A1
The present invention relates to a pyrrolopyrimidinone carboxamide compound represented by chemical formula 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for treating cancer, co...  
WO/2023/217094A1
Disclosed in the present invention are a preparation method and the use of 2'-deoxyguanosine, guanosine and a composition of 2'-deoxyguanosine and guanosine. The present invention belongs to the technical field of the prevention and cont...  
WO/2023/219114A1
The mRNA cap analog contains a functional group selected from the following: amino group, carboxylic acid active ester groups, aminooxy group, hydrazino group, carbonyl group, thiol group, haloacetyl groups, Michael acceptor functional g...  
WO/2022/221241A9
Compounds comprising 5-position modified pyrimidines are provided. Further, polynucleotides, such as aptamers, comprising at least one 5-position modified pyrimidine are provided. Methods of selecting and using such polynucleotides, such...  
WO/2023/215506A1
In one aspect, the disclosed technology relates to nanopore sequencing with a polynucleotide comprising a plurality of nucleotides, wherein each nucleotide comprises a linker construct between two positions of the nucleotide, wherein the...  
WO/2023/215516A2
Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2'-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present di...  
WO/2023/212656A1
Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell po...  
WO/2023/209586A1
The present invention relates to new glycomimetic molecules which selectively bind to the L-SIGN receptor, finding application in the medical field and, in particular, in the prevention and treatment of viral infections, in the immunothe...  
WO/2023/205206A1
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods fo...  
WO/2023/202604A1
The present invention falls within the technical field of medicinal chemistry, and specifically relates to an antiviral nucleoside analogue, and a pharmaceutical composition and the use thereof. The nucleoside analogue of the present inv...  
WO/2023/205786A1
The invention provides substituted 2',3'-didehydro-3'-deoxy-4'-ethynylthymidines and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase activity, their use for inhibiting HERV-K reverse t...  
WO/2023/178133A9
The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcrip...  
WO/2023/201072A1
In various embodiments of the present disclosure, antiviral 6-azauridine compounds are described having a structure represented by Formula (I) and comprising 6-azauridine tri-ester, phosphoramidate, and cyclic phosphoramidate monophospha...  
WO/2023/200760A1
The invention relates to new tunicamycin structures comprising N-acyl groups metabolically integrated into the terminus of the TUN via the Streptomyces branched chain fatty acid pathways and variants thereof, and methods of preparing suc...  
WO/2023/197791A1
The present invention relates to a cyclic carbonate nucleoside compound as represented by formula (I), and a pharmaceutically acceptable salt, a crystalline hydrate, a solvate or a tautomer thereof, and further disclosed are a pharmaceut...  

Matches 1 - 50 out of 9,624